Multicenter randomized controlled study of Complete Degradable Drug-Eluting Vascular Stent System versus drug-coated balloon for treatment of superficial femoral artery stenosis or occlusion
Multicenter randomized controlled study of Complete Degradable Drug-Eluting Vascular Stent System versus drug-coated balloon for treatment of superficial femoral artery stenosis or occlusion
This study evaluated the safety and efficacy of the Complete Degradable Drug-Eluting Vascular Stent System (CD-DVS) for superficial femoral artery (SFA) stenosis or occlusion. In this prospective multicenter randomized controlled trial, 106 patients enrolled between May 2023 and June 2024 were randomly assigned to the CD-DVS group (n = 53) or the drug-coated balloon (DCB) group (n = 53). The primary endpoint was primary patency at 30 days, 90 days, 180 days, and 12 months. Secondary endpoints included device/procedural success, Rutherford classification, ankle–brachial index (ABI), and major adverse cardiovascular events. Baseline characteristics were comparable between groups. Primary patency at 30 days was 100% in both groups. At 90 days, patency was 100% in the CD-DVS group versus 90.57% in the DCB group (P = 0.067). At 12 months, the CD-DVS group demonstrated significantly higher primary patency than the DCB group (96.00% vs. 82.35%, P = 0.025). Device and procedural success rates were 100% in both groups. The CD-DVS group showed significantly better Rutherford classification and higher ABI at 180 days and 12 months. No severe adverse events were observed. CD-DVS appears safe and effective for SFA stenosis or occlusion, providing superior 12-month patency and ABI improvement compared with DCB.
Li-Zhao Wang, Qiang Dong, Yan Gu.
Multicenter randomized controlled study of Complete Degradable Drug-Eluting Vascular Stent System versus drug-coated balloon for treatment of superficial femoral artery stenosis or occlusion.
MedScience DOI:10.1007/s11684-026-1277-0
This article has successfully passed peer review and final editorial review, and will soon enter typesetting, proofreading and other publishing processes. The currently displayed version is the accepted final manuscript. The officially published version will be updated with format, DOI and citation information upon launch. We recommend that you pay attention to subsequent journal notifications and preferentially cite the officially published version. Thank you for your support and cooperation.